{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:42:37Z","timestamp":1785483757099,"version":"3.56.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Dev Behav Pediatr"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>As understanding of the neurobiological basis of cognitive impairment in Down syndrome (DS) advances and new pharmaceutical interventions targeting neurodevelopment become available, an in-depth understanding of the family perspective is essential to inform research efforts. A mixed methods study was conducted with parents of individuals with DS to learn about attitudes toward pharmacological interventions to enhance cognition, participation in clinical research trials in DS, and the relationship between child\/family-specific factors and parent attitudes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>Parents completed an online survey (N = 37) assessing family\/child sociodemographic factors and to capture thoughts on cognitive enhancement and participation in clinical drug trials. A subset of interested parents participated in a follow-up phone interview (N = 21) or focus group (N = 3; 1 FG). Double-blind thematic analysis was used to analyze qualitative data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Parents' attitudes toward improving cognition, reversing intellectual disability, and participation in clinical trials correlated with each other and were informed by specific parent and child factors (e.g., child attention-deficit hyperactivity disorder\/behavioral diagnosis and parent education). Qualitative themes included advantages, disadvantages, and ethical implications of enhancing cognition. In addition, themes emerged regarding the need to understand the mechanism and potential side effects of experimental drugs, logistical factors relating to willingness to participate in clinical trials, and the evolution of parents' attitudes over time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The findings highlight the complexity of issues and implications of clinical trials for enhancing cognition in DS. Child-specific factors, logistical and safety considerations, and personal belief systems all inform parent attitudes and decision making. The findings reflect the importance of incorporating parent perspectives and values in research direction and design.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dbp.0000000000000900","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T20:17:16Z","timestamp":1613074636000},"page":"380-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Parent Attitudes Toward Enhancing Cognition and Clinical Research Trials in Down Syndrome: A Mixed Methods Study"],"prefix":"10.1097","volume":"42","author":[{"given":"Kirsten M.","family":"Christensen","sequence":"first","affiliation":[{"name":"Department of Psychology, University of Massachusetts Boston, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hojlo","sequence":"additional","affiliation":[{"name":"Division of Developmental Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Milliken","sequence":"additional","affiliation":[{"name":"Division of Developmental Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole T.","family":"Baumer","sequence":"additional","affiliation":[{"name":"Division of Developmental Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA;"},{"name":"Department of Neurology, Boston Children's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"R1-20250530","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(03)12987-X","article-title":"Down syndrome","volume":"361","author":"Roizen","year":"2003","journal-title":"Lancet."},{"key":"R2-20250530","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-444-54299-1.00006-6","article-title":"Neurological phenotypes for Down syndrome across the life span","volume":"197","author":"Lott","year":"2012","journal-title":"Prog Brain Res."},{"key":"R3-20250530","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lesson learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"R4-20250530","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/WCO.0000000000000703","article-title":"Emerging pharmacological therapies in fragile X syndrome and autism","volume":"32","author":"Yamasue","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"R5-20250530","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/WCO.0000000000000542","article-title":"Clinical trials in autism spectrum disorder: evidence, challenges, and future directions","volume":"31","author":"Anagnostou","year":"2018","journal-title":"Curr Opinions Neurol."},{"key":"R6-20250530","doi-asserted-by":"crossref","first-page":"321fs1","DOI":"10.1126\/scitranslmed.aad9874","article-title":"Clinical trials for neurodevelopmental disorders: at a therapeutic frontier","volume":"8","author":"Jeste","year":"2016","journal-title":"Sci Transl Med."},{"key":"R7-20250530","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1515\/rns.2011.037","article-title":"Is it possible to improve neurodevelopmental abnormalities in Down syndrome?","volume":"22","author":"Bartesaghi","year":"2011","journal-title":"Rev Neurosci."},{"key":"R8-20250530","doi-asserted-by":"crossref","first-page":"584071","DOI":"10.1155\/2012\/584071","article-title":"Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities","volume":"2012","author":"Rueda","year":"2012","journal-title":"Neural Plasticity."},{"key":"R9-20250530","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.biopsych.2011.08.016","article-title":"Neurobiological elements of cognitive dysfunction in Down syndrome: exploring the role of APP","volume":"71","author":"Sanchez","year":"2012","journal-title":"Biol Psychiatry."},{"key":"R10-20250530","first-page":"103","article-title":"Pharmacological approaches to improving cognitive function in Down syndrome: current status and consideration","volume":"9","author":"Gardiner","year":"2015","journal-title":"Drugs Des Develop Ther."},{"key":"R12-20250530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1352\/1944-7558-125.1.1","article-title":"Evaluating the risk and benefits of genetic and pharmacological interventions for Down syndrome: views of parents","volume":"125","author":"Riggan","year":"2020","journal-title":"Am J Intellect Dev Disabil."},{"key":"R13-20250530","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/ajmg.a.38465","article-title":"Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: strides to date","volume":"173","author":"Hart","year":"2017","journal-title":"Am J Med Genet A."},{"key":"R14-20250530","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-016-0353-4","article-title":"Improving memory and cognition in individuals with Down syndrome","volume":"30","author":"Rafii","year":"2016","journal-title":"CNS Drugs."},{"key":"R15-20250530","doi-asserted-by":"crossref","first-page":"13843","DOI":"10.1523\/JNEUROSCI.2775-15.2015","article-title":"New perspectives for the rescue of cognitive disability in Down syndrome","volume":"35","author":"Bartesaghi","year":"2015","journal-title":"J Neurosci."},{"key":"R16-20250530","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.12364","article-title":"A \u201ccure\u201d for Down syndrome: what do parents want?","volume":"86","author":"Inglis","year":"2014","journal-title":"Clin Genet."},{"key":"R17-20250530","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ajmg.a.33595","article-title":"Understanding attitudes towards people with Down syndrome","volume":"152","author":"Pace","year":"2010","journal-title":"Am J Med Genet."},{"key":"R18-20250530","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.socscimed.2004.05.020","article-title":"Between \u201cdesperation\u201d and disability rights: a narrative analysis of complementary\/alternative medicine use by parents for children with Down syndrome","volume":"60","author":"Prussing","year":"2005","journal-title":"Soc Sci Med."},{"key":"R19-20250530","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nature12394","article-title":"Translating dosage compensation to trisomy 21","volume":"500","author":"Jiang","year":"2013","journal-title":"Nature."},{"key":"R20-20250530","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10897-017-0111-x","article-title":"Parental perspectives on pharmacological clinical trials: a qualitative study in Down syndrome and fragile X syndrome","volume":"26","author":"Reines","year":"2017","journal-title":"J Genet Couns."},{"key":"R22-20250530","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1215\/08992363-13-3-533","article-title":"Enabling disability: rewriting kinship, reimagining citizenship","volume":"13","author":"Rapp","year":"2001","journal-title":"Public Cult."},{"key":"R23-20250530","first-page":"1408","article-title":"Are we there yet? Data saturation in qualitative research","volume":"20","author":"Fusch","year":"2015","journal-title":"Qual Rep."}],"container-title":["Journal of Developmental &amp; Behavioral Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:02:02Z","timestamp":1748628122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dbp.0000000000000900","relation":{},"ISSN":["0196-206X"],"issn-type":[{"value":"0196-206X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"2020-06-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}